Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Pipeline Review, H1 2017

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Pipeline Review, H1 2017


  • Products Id :- GMDHC0885TDB
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Pipeline Review, H1 2017

Summary

According to the recently published report Aryl Hydrocarbon Receptor-Pipeline Review, H1 2017 Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.

The report Aryl Hydrocarbon Receptor-Pipeline Review, H1 2017 outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type that are being developed by Companies / Universities.

It also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Immunology which include indications Breast Cancer, Type 1 Diabetes (Juvenile Diabetes), Androgen-Sensitive Prostate Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Multiple Sclerosis, Obesity, Osteoporosis, Ovarian Cancer, Solid Tumor and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)

The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects

The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Overview

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Companies Involved in Therapeutics Development

Hercules Pharmaceuticals BV

Nippon Kayaku Co Ltd

Shenogen PharmaGroup Ltd

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Drug Profiles

CB-7993113-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDR-914K058-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinnabarinic acid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITE-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-150460-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-162-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Dormant Products

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)-Product Development Milestones

Featured News & Press Releases

Nov 02, 2015: Hercules Receives EURO3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer

Sep 15, 2015: Icaritin Enters Fast Track Review for NDA

Sep 18, 2014: Icaritin Ph I Result Presents at 2014 CSCO

Jun 13, 2013: Shenogen PharmaGroup: Icaritin Phase II advisory meeting held in Beijing

Jun 07, 2013: Icaritin Phase I data presented at 2013 ASCO Annual Meeting: June 3rd, 2013

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Hercules Pharmaceuticals BV, H1 2017

Pipeline by Nippon Kayaku Co Ltd, H1 2017

Pipeline by Shenogen PharmaGroup Ltd, H1 2017

Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Hercules Pharmaceuticals BV

Nippon Kayaku Co Ltd

Shenogen PharmaGroup Ltd

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Therapeutic Products under Development, Key Players in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Therapeutics, Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Pipeline Overview, Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Pipeline, Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Pipeline Assessment

select a license
Single User License
USD 3500 INR 245000
Site License
USD 7000 INR 490000
Corporate User License
USD 10500 INR 735000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com